Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Pavle Sitarica"VINČA" Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.ORCID 0009-0006-4209-0640
Aleksandar Vukadinović"VINČA" Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.ORCID 0000-0002-9352-8036
Miloš Marić"VINČA" Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.ORCID 0009-0007-0110-7482
Sanja Vranješ-Đurić"VINČA" Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.
Dalibor Stanković"VINČA" Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.ORCID 0000-0001-7465-1373
Marko Perić"VINČA" Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.
Drina Janković"VINČA" Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.ORCID 0000-0003-3938-2790
Dragana Stanković"VINČA" Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.ORCID 0000-0001-7669-2865
Marija Mirković"VINČA" Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.ORCID 0000-0002-3176-5554
Magdalena Radović"VINČA" Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.ORCID 0000-0002-3972-313X
Funding
Ministry of Science, Technological Development, and Innovation of the Republic of Serbia 451-03-136/2025-03/200017; 003417078 2024 013440 003 000 620 021Science Fund of the Republic of Serbia 7282
6 · The paper itself
Abstract
Two diphosphonates, etidronic acid (HEDP) and zoledronic acid (ZOL), were radiolabelled with
Indexed as
Bone and BonesDiphosphonatesRadiopharmaceuticalsAnimalsEtidronic AcidHumansMaleRatsRats, WistarTissue DistributionZoledronic AcidDiphosphonatesEtidronic AcidRadiopharmaceuticalsZoledronic Acid161Tb-labeled diphosphonatesbiodistributionbone-targetingDFTelectrochemical behaviorHEDPhydroxyapatite bindingZOL
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.